seen from Brazil
seen from Pakistan
seen from United States
seen from France
seen from Canada
seen from Mexico
seen from Canada
seen from Hungary
seen from Canada
seen from United States
seen from Canada
seen from Türkiye
seen from United States
seen from Canada
seen from United States
seen from China
seen from Kazakhstan
seen from Japan
seen from United States
seen from Canada
Pharmaceutical firms boost global health through innovation & pharma magazines, latest biotech news, pharmaceutical newsletter with quality
Pharmaceutical firms boost global health through innovation & pharma magazines, latest biotech news, pharmaceutical newsletter with quality at core. For info visit us https://www.worldpharmatoday.com/ , Call us at 9397998765
Pharmaceutical firms boost global health through innovation & pharma magazines, latest biotech news, pharmaceutical newsletter with quality at core.
Maurizio Luongo, CEO, A. Menarini Asia-Pacific Holdings Pte Ltd. (Menarini Asia-Pacific) shared his views with Pharma Focus Asia on “Building a Biomedical Diagnostic Research Hub in Asia”.
Why the need to launch a biomarker research arm?
Menarini Biomarkers (A. Menarini Biomarkers Singapore Pte Ltd) was founded with the mission of identifying, developing, and validating new biomarkers on circulating human cells for applications in diagnostics.
There is a current healthcare gap in precision medicine surrounding the fields of early disease prediction and disease control, particularly related to precision rare-cell isolation, analysis, and disease diagnosis. Menarini Biomarkers uses single-cell analysis to provide clinicians with new tools for early detection, tracking disease progression, and the measurement of real-time responses to innovative therapies.
The R&D team specialises in pathogenic single-cell isolation that enables scientists to pinpoint specific disease markers, also known as biomarkers. The identification and selection of pathogenic single cells from blood samples is incredibly useful in disease treatment, as it helps healthcare practitioners narrow therapies down to target cells.
Read More : https://www.pharmafocusasia.com/research-development/building-biomedical-diagnostic-research
Genetic testing can be used to reduce the risk of experiencing adverse reactions. Seldom is one single gene responsible for altering a drug’s benefitrisk balance. This is more often due to multiple genetic and non-genetic factors, thus increasing the complexity and limiting the utility of a widespread use of pharmacogenomics. Widespread use of genotyping and artificial intelligence can overcome these limits.
Pharmacogenomics is the study of the genes, their structure, function, polymorphisms, transcription, and translation, how they interact with each other and with environment. The main goal of pharmacogenomics is to understand how genetic variants can alter a drug’s benefit-risk balance. Genetic differences that are likely to be of most relevance to drugs and that can alter their benefit-risk balance pertain to four broad categories.
Read More: https://www.pharmafocusasia.com/research-development/pharmacogenomic-information
Daphne Teo, CEO and Founder of NSG BioLabs, shares her insights & understanding of the innovative biotech ecosystem in Singapore & Asia. She elaborates on the opportunities for biotech startups and the kind of support they need to solve some of the biggest medical challenges of the 21st century.
Read More: https://www.pharmafocusasia.com/expert-talk/innovative-biotech-ecosystem-singapore-asia
Through the years pharmaceutical companies have managed to apply Operational Excellence (OPEX) and Lean-thinking to their operations. Nevertheless, the majority still lacks behind when incorporating an end-to-end perspective. A first step to holistically assess the performance of pharmaceutical companies necessarily incorporates quality control (QC) in addition to manufacturing. Therefore, the St.Gallen QC Lab Benchmarking helps to position pharmaceutical QC labs from a broad range of pharmaceutical companies against each other.
